These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 12170449)

  • 21. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
    Heinemann V
    Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC).
    Boér K; Láng I; Juhos E; Pintér T; Szántó J
    Pathol Oncol Res; 2003; 9(3):166-9. PubMed ID: 14530809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].
    Fattoruso SI; Rossi S; Vici P; Di Filippo F; Botti C; Di Lauro L; Foggi P; Saracca E; Ferranti FR; Visca P; Lopez M
    Clin Ter; 2008; 159(6):443-7. PubMed ID: 19169606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
    Nabholtz JM; Mackey JR; Smylie M; Paterson A; Noël DR; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
    J Clin Oncol; 2001 Jan; 19(2):314-21. PubMed ID: 11208821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
    Di Leo A; Crown J; Nogaret JM; Duffy K; Bartholomeus S; Dolci S; Rowan S; O'Higgins N; Paesmans M; Larsimont D; Riva A; Piccart MJ
    Ann Oncol; 2000 Feb; 11(2):169-75. PubMed ID: 10761751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospects with docetaxel in the treatment of patients with breast cancer.
    Marty M; Extra JM; Cottu PH; Espié M
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
    Pegram MD; O'Callaghan C
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
    Nabholtz JM; Mackey J; Smylie M; Tonkin K
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):27-31. PubMed ID: 9865709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
    Nabholtz JM; Riva A
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
    Crown J; Pegram M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
    Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
    Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.